The therapeutic potential of GPR120: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 12, 2013, Pages 1581-1590

  Halder, Somnath ^a   Kumar, Sanjay ^a   Sharma, Rajiv ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Diabetes; G protein coupled receptors; GLP 1; GPR120; GPR40; GSIS; Inflammation; Insulin; Metabolic disorders; Obesity

Indexed keywords

G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 120 STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; UNCLASSIFIED DRUG;

AGONIST; DIABETES MELLITUS; DRUG DATABASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NONHUMAN; PATENT; PREVALENCE; REVIEW;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84890063785     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.842977     Document Type: Review

References (40)

1. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 2003;116:4867-9
2. Ellis C. The state of GPCR research in 2004. Nat Rev Drug Discov 2004; 3:577-626
3. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA 2003;100:4903-8
4. Talukdar S, OLefsky JM, Osborn O. Targeting GPR120 and other fatty acid sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 2011;32:543-50
5. Hamm HE. How activated receptors couple to G proteins. Proc Natl Acad Sci USA 2001;98:4819-21
6. Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Disc 2012;11:603-19
7. Miyauchi S, Hirasawa A, Ichimura A, et al. New frontiers in gut nutrient sensor research: Free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci 2010;112:19-24
8. Haber EP, Ximenes HM, Procópio J, et al. Pleiotropic effects of fatty acids on pancreatic beta-cells. J Cell Physiol 2003;194:1-12
9. Holliday ND, Watson SJ, Brown AJH. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids. Front Endocrinol 2012;2:1-12
10. Milligan G, Stoddart LA, Brown AJ. G Protein-coupled receptors for free fatty acids. Cell Signal 2006;18:1360-5
11. Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010;1:290-4
12. Lin DCH, Zhang J, Zhuang R, et al. AMG837: A novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 2011;6:e27270
13. Christiansen E, Urban C, Grundmann M, et al. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favourable physicochemical and in vitro ADME properties. J Med Chem 2011;54:6691-703
14. Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules. Br J Pharmacol 2006;14:619-28
15. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-4
16. Mobraten K, Haug TM, Kleiveland CR, et al. Omega-3 and omega-6 PUFAs induce the same GPR120-mediated signalling events, but with different kinetics and intensity in Caco-2 cells. Lipids Health Dis 2013; 12:101
17. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell 2010;142: 687-98
18. The regents of the University of California. Methods of treating inflammatory conditions. WO072132; 2011
19. Ichimura A, Hirasawa A, Godefroy OP, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012;483:350-4
20. Shimpukade B, Hudson BD, Hovgaard CK, et al. Discovery of a potent and selective GPR120 agonist. J Med Chem 2012;55:4511-15
21. Hara T, Hirasawa A, Sun Q, et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol 2009;380:247-55
22. Sun Q, Hirasawa A, Hara T, et al. Structure activity relationships of GPR120 agonists based on a docking simulation. Mol Pharmacol 2010; 78:804-10
23. Japan Science and Technology Agency. G- protein conjugated receptor agonists. WO139987; 2008
24. Takeuchi M, Hirasawa A, Hara T, et al. FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models. Br J Pharmacol 2013;168:1570-83
25. Suzuki T, Igari SI, Hirasawa A, et al. Identification of G protein-coupled receptor 120-selective agonists derived from PPARg agonists. J Med Chem 2008;51:7640-4
26. Tsujimoto G, Hirasawa A, Miyata N, et al. G- protein conjugated receptor agonists. US0184031; 2011
27. Wu Q, Wang H, Zhao X, et al. Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 2013; doi: 10.1038/onc.2013.264
28. IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO103501; 2008
29. IRM LLC. Thiazole derivatives as modulators of G-protein coupled receptors. WO103500; 2008
30. IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO008831; 2010
31. IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO121570; 2008
32. Metabolex, Inc. GPR120 receptor agonists and uses thereof. WO080537; 2010
33. Metabolex, Inc. GPR120 receptor agonists and uses thereof. WO159297; 2011
34. Metabolex, Inc. Aryl GPR120 receptor agonists and uses thereof. WO048207; 2010
35. Banyu Pharmaceutical Co. Ltd. Novel isoindolin-1-one derivative. WO104195; 2010
36. Daewoong Pharmaceutical Co. Ltd. 3- cyclopentyloxy-4- methoxyphenylisothiazolinone derivatives and use thereof. WO081447; 2002
37. Daewoong Pharmaceutical Co. Ltd. Novel 3,4-dialkoxyphenyl derivatives and use thereof. WO42666; 1998
38. Banyu Pharmaceutical Co. Ltd. Novel phenyl-isoxazol-3-ol derivative. US0130559; 2010
39. Kindex Therapeutics LLC. cis 3,4-dihydroxy -2-(3-methylbutanoyl) -5-(-3-methylbutyl) -4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods. WO058649; 2012
40. Pharma Frontier Co. Ltd. Novel long chain fatty acid derivative compound and G protein coupled receptor agonist containing the compound as active ingredient. WO038204; 2009